Interferon responses in HIV infection: From protection to disease

AIDS Reviews

Volumn 16, Issue 1, 2014, Pages 43-51

  Sivro, Aida ^a   Su, Ruey Chyi ^a   Plummer, Francis A ^a   Ball, T Blake ^a,b,c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

Disease progression; HESN; HIV AIDS; IFN therapy; Interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CHLOROQUINE; DIDANOSINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; VIRUS VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACUTE DISEASE; ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INFECTION PREVENTION; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION; CLINICAL TRIAL; HIV INFECTIONS;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; INTERFERONS;

EID: 84896895575     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Pestka, S. The Interferons: 50 Years after Their Discovery, There Is Much More to Learn. J Biol Chem. 2007;282:20047-51. (Pubitemid 47099975)
2. Pestka, S, Krause C, Walter M. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8-32.
3. de Weerd N, Nguyen T. The interferons and their receptors - distribution and regulation. Immunol Cell Biol. 2012;90:483-91.
4. González-Navajas J, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12:125-35.
5. Pestka S, Krause C, Walter M. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8-32. (Pubitemid 39576902)
6. Schoenborn J, Wilson C. In: Advances in immunology. Elsevier. 2007; 96:41-101.
7. Sommereyns C, Paul S, Staehel P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4:e1000017.
8. Siegal F, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835-7.
9. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008;19:3-19.
10. Sadler A, Williams B. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559-68. (Pubitemid 351913674)
11. Haller O, Staeheli P, Kochs G. Interferon-induced Mx proteins in antiviral host defense. Biochimie. 2007;89:812-18. (Pubitemid 47001645)
12. Karupiah G, Xie Q, Buller R, Nathan C, Duarte C, MacMicking J. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science. 1993;261:1445-8. (Pubitemid 23334265)
13. Prchal M, Pilz A, Simma O, et al. Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity. Vaccine. 2009;27:G17-20.
14. Levy D, García-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 2001;12:143-56. (Pubitemid 32590836)
15. Katze M, He Y, Gale M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002;2:675-87. (Pubitemid 37328725)
16. Zimring J, Goodbourn S, Offermann M. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J Virol. 1998;72:701-7. (Pubitemid 28048889)
17. Lubyova B, Pitha P. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol. 2000;74:8194-201. (Pubitemid 30641667)
18. Mcmichael A, Borrow P, Tomaras G, Goonetilleke N, Haynes B. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2009;10:11-23.
19. Bishop K, Verma M, Kim E-Y, Wolinsky S, Malim M. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008;4:e1000231.
20. Bogerd H, Doehle B, Wiegand H, Cullen B. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA. 2004;101:3770-4. (Pubitemid 38381053)
21. Mbisa J, Barr R, Thomas J, et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol. 2007;81:7099-110. (Pubitemid 46986646)
22. Yan N, Chen Z. Intrinsic antiviral immunity. Nat Immunol. 2012;13:214-22.
23. Malim M, Bieniasz P. HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med. 2012;2:a006940.
24. Wang F, Huang J, Zhang H, Ma X, Zhang H. APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. J Gen Virol. 2008;89:722-30.
25. Michaelis B, Levy JA. HIV replication can be blocked by recombinant human interferon beta. AIDS. 1989;3:27-31. (Pubitemid 19058454)
26. Hou W, Wang X, Ye L, et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009;83:3834-42.
27. Yan N, Lieberman J. Gaining a foothold: how HIV avoids innate immune recognition. Curr Opin Immunol. 2011;23:21-8.
28. Horton R, McLaren P, Fowke K, Kimani J, Ball T. Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J Infect Dis. 2010;202:S377-81.
29. Biasin M, Piacentini L, Lo Caputo S, et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3g: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis. 2007;195:960-4. (Pubitemid 46452100)
30. Montoya C, Velilla P, Chougnet C, Landay A, Rugeles M. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol. 2006;120:138-46. (Pubitemid 44080673)
31. Scott-Algara D, Truong L, Versmisse P, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol. 2003;171:5663-7. (Pubitemid 37467178)
32. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31:429-34. (Pubitemid 35154456)
33. Boulet S, Sharafi S, Simic N, et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS. 2008;22:595-9. (Pubitemid 351640592)
34. Long B, Ndhlovu L, Oksenberg J, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol. 2008;82:4785-92. (Pubitemid 351657040)
35. Alter G, Martin MP, Teigen N, et al. Differential natural killer cell mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med. 2007;204:3027-36. (Pubitemid 350179568)
36. Ji H, Ball T, Kimani J, Plummer F. Novel interferon regulatory factor-1 polymorphisms in a Kenyan population revealed by complete gene sequencing. J Hum Genet. 2004;49:528-35. (Pubitemid 39516981)
37. Ball T, Ji H, Kimani J, et al. Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS. 2007;21:1091-101. (Pubitemid 46763279)
38. Ji H, Ball T, Ao Z, Kimani J, Yao X, Plummer F. Reduced HIV-1 long terminal repeat transcription in subjects with protective interferon regulatory factor-1 genotype: a potential mechanism mediating resistance to infection by HIV-1. Scand J Infect Dis. 2010;42:389-94.
39. Sivro A, McKinnon LR, Ji H, et al. Interferon regulatory factor 1 polymorphisms previously associated with reduced HIV susceptibility have no effect on HIV disease progression. PLoS One. 2013;8:e66253.
40. Su R, Sivro A, Kimani J, Jaoko W, Plummer F, Ball T. Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals. Blood. 2011;117:2649-57.
41. Haase A. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med. 2011;62:127-39.
42. Stacey A, Norris P, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83:3719-33.
43. Borrow P. Innate immunity in acute HIV-1 infection. Curr Opin HIV AIDS. 2011;6:353-63.
44. Alter G, Teigen N, Ahern R, et al. Evolution of innate and adaptive effector cell functions during acute HIV?1 infection. J Infect Dis. 2007; 195:1452-60. (Pubitemid 46717463)
45. Herbeuval J, Shearer G. HIV-1 immunopathogenesis: How good interferon turns bad. Clin Immunol. 2007;123:121-8. (Pubitemid 46590066)
46. Schmidt B, Scott I, Whitmore R, et al. Low-level HIV infection of plasmacytoid dendritic cells: onset of cytopathic effects and cell death after PDC maturation. Virology. 2004;329:280-8. (Pubitemid 39423978)
47. Machmach K, Leal M, Gras C, et al. Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol. 2012;86:4245-52.
48. Fenton-May A, Dibben O, Emmerich T, et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology. 2013;10.146.
49. Gasper-Smith N, Crossman D, Whitesides J, et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol. 2008;82:7700-10. (Pubitemid 352031235)
50. Fitzgerald-Bocarsly P, Jacobs E. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. J Leukoc Biol. 2010;87:609-20.
51. Zhou D, Kang K, Spector S. Production of interferon ± by human immunodeficiency virus type 1 in human plasmacytoid dendritic cells is dependent on induction of autophagy. J Infect Dis. 2012;205:1258-67.
52. Hardy A, Graham D, Shearer G, Herbeuval J. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN. Proc Nat Acad Sci USA. 2007;104:17453-8. (Pubitemid 350219859)
53. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep. 2007;4:10-15. (Pubitemid 46555246)
54. Mehandru S. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-70. (Pubitemid 39299462)
55. Kontsek P, Borecký L, Novák M. Are the acid-labile interferon alpha and interferon omega-1 identical? Virology. 1991;181:416-8.
56. Minagawa T, Mizuno K, Hirano S, et al. Detection of high levels of immunoreactive human beta-1 interferon in sera from HIV-infected patients. Life Sci. 1989;45:iii-vii. (Pubitemid 19251920)
57. Navikas V, Link J, Wahren B, Persson C, Link H. Increased levels of interferon-gamma (IFN-γ), IL-4 and transforming growth factor-beta (TGF-β) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol. 2008;96:59-63.
58. DeStefano E, Friedman RM, Friedman-Kien AE, et al. Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis. 1982;146:451-5. (Pubitemid 12004441)
59. Lehmann C, Lafferty M, Garzino-Demo A, et al. Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One. 2010;5:e11110.
60. Hardy G, Sieg S, Rodriguez B, et al. Interferon-α Is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One. 2013;8:e56527.
61. Boasso A, Herbeuval J, Hardy A. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood. 2007;109:3351-9. (Pubitemid 46572523)
62. Boasso A, Hardy A, Anderson S, Dolan M, Shearer G. HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One. 2008;3:e2961 (2008).
63. Manches O, Munn D, Fallahi A, et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest. 2008;118:3431-9.
64. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-71. (Pubitemid 44924494)
65. Harris L, Tabb B, Sodora D, et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol. 2010;84:7886-91.
66. Jacquelin B, Mayau V, Targat B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009;119:3544-55.
67. Torre D, Ferrario G, Speranza F, Orani A, Fiori G, Zeroli C. Serum concentrations of nitrite in patients with HIV-1 infection. J Clin Pathol. 1996;49:574-6. (Pubitemid 26232733)
68. Zangerle R, Fuchs D, Reibnegger G, et al. Serum nitrite plus nitrate in infection with human immunodeficiency virus type-1. Immunobiology. 1995;193:59-70.
69. Torre D, Ferrario G, Bonetta G, Speranza F, Zeroli C. Production of nitric oxide from peripheral blood mononuclear cells and polymorphonuclear leukocytes of patients with HIV-1. AIDS. 1995;9:979-80.
70. Torre D, Pugliese A, Speranza F. Role of nitric oxide in HIV-1 infection: friend or foe? Lancet Infect Dis. 2002;2:273-80. (Pubitemid 34464738)
71. Liu X. Human immunodeficiency virus type 1 (HIV-1) Tat induces nitric-oxide synthase in human astroglia. J Biol Chem. 2002;277:39312-19. (Pubitemid 35190903)
72. Epstein L, Gendelman H. Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms. Ann Neurol. 1993;33:429-36. (Pubitemid 23143022)
73. Dawson V, Dawson T. Nitric oxide neurotoxicity. J Chem Neuroanat. 1996;10:179-90. (Pubitemid 26197684)
74. Gringeri A, Santagostino E, Cusini M, et al. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:55-67.
75. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-[alpha] immunization: A European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS Study). J Acquir Immune Defic Syndr. 1999;20:358-70. (Pubitemid 29143030)
76. Ries M, Pritschet K, Schmidt B. Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation. Clin Dev Immunol. 2012;2012;534929.
77. Martinson J, Montoya C, Usuga X, Ronquillo R, Landay A, Desai S. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother. 2010;54:871-81.
78. Murray, S. M. et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010;84:12082-6.
79. Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011;118:3263-72.
80. Paton N, Goodall R, Dunn D, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA 2012;308:353-61.
81. Azzoni L, Foulkes A, Papasavvas E, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. 2013;207:213-22.
82. Yola A, Sologub T, Nechaev V, Ivanov A. Immune-based therapy using gamma interferon ingaron in the treatment of HIV/AIDS patients with active pulmonary tuberculosis (PTB) not previously highly active antiretroviral therapy (HAART). Retrovirology. 2006;3:S38.
83. Krown S, Li P, Von Roenn J, Paredes J, Huang J, Testa M. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res. 2002;22:295-303. (Pubitemid 34499710)
84. Krown S, Lee J, Lin L, Fischl M, Ambinder R, Von Roenn J. Interferonalpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr. 2006;41:149-53.
85. Dominguez S, Ghosn J, Valantin M, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20:1157-61. (Pubitemid 43786104)
86. Muir A, Shiffman M, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822-32.